Moreover, anti-PD-1 antibodies nivolumab and pembrolizumab were also approved for the treatment of advanced HCC as the second-line regimens when combined with the anti-CTLA4 antibody ipilimumab [181] and administrated as a monotherapy [182], respectively. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.